Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nplate romiplostim: Phase III data

In a double-blind Phase III trial in 63 post-splenectomy ITP patients, 16 of 42 of patients (38%) who received

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE